Glancy Prongay & Murray LLP ("GPM") reminds investors that a class action complaint has been filed on behalf of a class of Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NASDAQ: OSIR) investors who purchased shares between May 12, 2014 and November 20, 2015, inclusive (the "Class Period"). Osiris investors are encouraged to contact GPM to discuss their legal rights.

On November 16, 2015, the Company announced that it has, "determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015." On this news shares of Osiris fell over 21% to close at $10.97 per share on November 17, 2015. Then on December 17, 2015, the Company disclosed that the Company's independent auditor BDO USA, LLP had resigned on December 14, 2015. On this news shares of Osiris fell a further 10% per share, thereby injuring investors.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company overstated revenues from several contracts and failed to follow GAAP standards, fixing its financial statements only a year and half later and causing millions in losses to the Company and Investors; and (ii) as a result of the foregoing, Osiris's public statements were materially false and misleading at all relevant times.

If you purchased shares of Osiris during the Class Period you may move the Court no later than January 22, 2016 to request appointment as lead plaintiff, or if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to, or visit our website at If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010